Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 3.1 Exhibit 3.1
- 3.2 Exhibit 3.2
- 3.3 Exhibit 3.3
- 4.1 Exhibit 4.1
- 4.2 Exhibit 4.2
- 4.4 Exhibit 4.4
- 10.1 Exhibit 10.1
- 10.14 Exhibit 10.14
- 10.15 Exhibit 10.15
- 10.16 Exhibit 10.16
- 10.17 Exhibit 10.17
- 10.18 Exhibit 10.18
- 10.19 Exhibit 10.19
- 10.20 Exhibit 10.20
- 10.21 Exhibit 10.21
- 10.22 Exhibit 10.22
- 10.23 Exhibit 10.23
- 10.24 Exhibit 10.24
- 10.25 Exhibit 10.25
- 10.26 Exhibit 10.26
- 16.1 Exhibit 16.1
- 21.1 Exhibit 21.1
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- Download Excel data file
- View Excel data file
TLSI similar filings
- 14 Nov 23 TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update
- 3 Oct 23 Standby Equity Purchase Agreement
- 1 Sep 23 Regulation FD Disclosure
- 16 Aug 23 Entry into a Material Definitive Agreement
- 9 Aug 23 Submission of Matters to a Vote of Security Holders
- 2 Aug 23 MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders
- 2 Aug 23 Other Events
Filing view
External links
Exhibit 16.1
August 16, 2023
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Ladies and Gentlemen:
We have read the statements made by TriSalus Life Sciences, Inc. (“TriSalus”) included under Item 4.01 of its Form 8-K dated August 16, 2023. We agree with the statements concerning our Firm under Item 4.01, in which we were informed of our dismissal on August 10, 2023. We are not in a position to agree or disagree with other statements contained therein.
Very truly yours,
/s/ WithumSmith+Brown, PC
New York, New York